Evidence map›Paper›PMID 35881160›Full record

ArticleArchives of toxicology2022

Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver.

Heike Sprenger, Josef Daniel Rasinger, Helen Hammer, Wael Naboulsi, Elke Zabinsky, Hannes Planatscher, Michael Schwarz, Oliver Poetz, Albert Braeuning

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Heike SprengerDepartment of Food Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589, Berlin, Germany.
Josef Daniel RasingerInstitute of Marine Research (IMR), Postboks 1870 Nordnes, 5817, Bergen, Norway.
Helen HammerSIGNATOPE GmbH, Markwiesenstr. 55, 72770, Reutlingen, Germany.
Wael NaboulsiSIGNATOPE GmbH, Markwiesenstr. 55, 72770, Reutlingen, Germany.
Elke ZabinskyDepartment of Experimental and Clinical Pharmacology and Pharmogenomics, University of Tübingen, Wilhelmstr. 56, 72074, Tübingen, Germany.
Hannes PlanatscherSIGNATOPE GmbH, Markwiesenstr. 55, 72770, Reutlingen, Germany.
Michael SchwarzDepartment of Experimental and Clinical Pharmacology and Pharmogenomics, University of Tübingen, Wilhelmstr. 56, 72074, Tübingen, Germany.
Oliver PoetzSIGNATOPE GmbH, Markwiesenstr. 55, 72770, Reutlingen, Germany.
Albert BraeuningDepartment of Food Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589, Berlin, Germany. Albert.Braeuning@bfr.bund.de.ORCID 0000-0003-3810-027X
Signatope GmbH (Germany)Federal Institute for Risk Assessment · DEUniversity of Tübingen · DENatural and Medical Sciences Institute · DENorwegian Institute of Marine Research · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of the constitutive androstane receptor (CAR) may induce adaptive but also adverse effects in rodent liver, including the induction of drug-metabolizing enzymes, transient hepatocellular proliferation, and promotion of liver tumor growth. Human relevance of CAR-related adverse hepatic effects is controversially debated. Here, we used the chimeric FRG-KO mouse model with livers largely repopulated by human hepatocytes, in order to study human hepatocytes and their response to treatment with the model CAR activator phenobarbital (PB) in vivo. Mice received an intraperitoneal injection with 50 mg/kg body weight PB or saline, and were sacrificed after 72-144 h. Non-repopulated FRG-KO mice were used as additional control. Comprehensive proteomics datasets were generated by merging data obtained by targeted as well as non-targeted proteomics approaches. For the first time, a novel proteomics workflow was established to comparatively analyze the effects of PB on human and murine proteins within one sample. Analysis of merged proteome data sets and bioinformatics data mining revealed comparable responses in murine and human hepatocytes with respect to nuclear receptor activation and induction of xenobiotic metabolism. By contrast, activation of MYC, a key regulator of proliferation, was predicted only for mouse but not human hepatocytes. Analyses of 5-bromo-2'-deoxyuridine incorporation confirmed this finding. In summary, this study for the first time presents a comprehensive proteomic analysis of CAR-dependent effects in human and mouse hepatocytes from humanized FRG-KO mice. The data support the hypothesis that PB does induce adaptive metabolic responses, but not hepatocellular proliferation in human hepatocytes in vivo.

Indexed as

PhenobarbitalProteomicsAnimalsConstitutive Androstane ReceptorHepatocytesHumansLiverMiceMice, Inbred StrainsConstitutive Androstane ReceptorPhenobarbitalCAR activationHumanized miceLiver toxicityPhenobarbitalProteomics

Identifiers

PMID35881160
PMCPMC9352639
OpenAlexW4287921451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.